首页|息喘汤联合治疗慢性阻塞性肺疾病稳定期患者效果及对CXCL13、TLR4、细胞因子影响

息喘汤联合治疗慢性阻塞性肺疾病稳定期患者效果及对CXCL13、TLR4、细胞因子影响

扫码查看
目的 探讨息喘汤联合治疗慢性阻塞性肺疾病(COPD)稳定期患者效果及对趋化因子CXC配体 13(CXCL13)、Toll样受体4(TLR4)、细胞因子影响.方法 选取 2020 年 6 月—2022 年 6 月收治的COPD稳定期 128例,根据治疗方法不同将其分为观察组和对照组2 组各64 例.观察组给予息喘汤联合茚达特罗格隆溴铵治疗,对照组给予茚达特罗格隆溴铵治疗,疗程均为12 周.比较2 组治疗后临床效果,治疗前后肺功能、COPD评估测试(CAT)评分、6 min步行距离(6MWT)和血清CXCL13、TLR4、细胞因子,以及治疗期间不良反应发生情况.结果 治疗后,观察组总有效率(93.75%,60/64)高于对照组(76.56%,49/64)(P<0.05).治疗后,2 组第1 秒用力呼气容积(FEV1)、最大呼气流量(PEF)、FEV1/用力肺活量(FVC)和6MWT高于或长于治疗前,CAT评分和血清CXCL13、TLR4、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、白细胞介素-33(IL-33)低于治疗前;且观察组 FEV1、PEF、FEV1/FVC 和6MWT高于或长于对照组,CAT评分和血清CXCL13、TLR4、TNF-α、IL-8、IL-33 低于对照组(P<0.05).治疗期间,2组不良反应发生率比较差异无统计学意义(P>0.05).结论 息喘汤联合治疗COPD稳定期患者效果良好,可下调血清CXCL13 和TLR4 表达,降低血清细胞因子TNF-α、IL-8 和IL-33 水平.
Effects of Xichuan Decoction in the Treatment of Patients with COPD at Stable Stage and Its Impact on CXCL13,TLR4 and Cytokines
Objective To investigate the effect of combined treatment with Xichuan decoction on patients with chron-ic obstructive pulmonary disease(COPD)at stable stage and its impact on chemokine CXC ligand 13(CXCL13),Toll-like receptor 4(TLR4)and cytokines.Methods A total of 128 patients with COPD at stable stage were selected from June 2020 to June 2022 and divided into two groups according to different treatment methods:observation group(n =64)and control group(n =64).Observation group was treated with Xichuan decoction combined with Indacatrolonium Bromide,while control group was treated with Indacatrolonium Bromide,and the course of treatment was 12 weeks.The clinical effect,pulmonary function before and after treatment,COPD assessment test(CAT)score,6-minute walking distance(6MWT),serum CXCL13,TLR4 and cytokine levels,and the occurrence of adverse reactions during treatment were compared between the two groups.Results After treatment,the total effective rate of observation group(93.75%,60/64)was higher than that of con-trol group(76.56%,49/64)(P<0.05).After treatment,the first second forced expiratory volume(FEV1),peak expira-tory flow(PEF),FEV1/forced vital capacity(FVC)and 6MWT in the two groups were higher or longer than those before treatment,while CAT scores and serum CXCL13,TLR4,tumor necrosis factor-α(TNF-α),interleukin-8(IL-8)and inter-leukin-33(IL-33)were lower than those before treatment.FEV1,PEF,FEV1/FVC and 6MWT in observation group were higher or longer than those in control group,while CAT score,serum CXCL13,TLR4,TNF-α,IL-8 and IL-33 in observation group were lower than those in control group(P<0.05).During treatment,there was no significant difference in the inci-dence of adverse reactions between the two groups(P>0.05).Conclusion Combined treatment with Xichuan decoction for COPD patients at stable stage has a good effect,which can down-regulate the expression of serum CXCL13 and TLR4,and re-duce the levels of serum cytokines TNF-α,IL-8 and IL-33.

Pulmonary disease,chronic obstructiveStable stageXichuan decoctionChemokine CXC ligand 13Toll like receptor 4Tumor necrosis factor-αInterleukin-8Interleukin-33

马真、张晓阳、杨久清、邓敬华、孙文博、马艳东

展开 >

053000 河北 衡水,衡水市中医医院肺病科

053000 河北 衡水,衡水市中医医院肿瘤科

肺疾病,慢性阻塞性 稳定期 息喘汤 趋化因子CXC配体13 Toll样受体4 肿瘤坏死因子-α 白细胞介素-8 白细胞介素-33

河北省中医管理局科研项目

2020537

2024

转化医学杂志
海军总医院

转化医学杂志

CSTPCD
影响因子:0.671
ISSN:2095-3097
年,卷(期):2024.13(1)
  • 20